Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.
The last earnings update was 14 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Wave Life Sciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Wave Life Sciences's
is considered below, and whether this is a fair price.
Price based on past earnings
Wave Life Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Wave Life Sciences's earnings are expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).
Wave Life Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Wave Life Sciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Wave Life Sciences
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Wave Life Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Wave Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Wave Life Sciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Wave Life Sciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 9.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Paul B. Bolno, M.D., MBA has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior to joining WAVE, Dr. Bolno served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President of Worldwide Business Development, Head of Asia BD & Investments, Head of Global Neuroscience BD, a Director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President of Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline’s global oncology business and served as a Member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as the Director of Research at Two River Group Holdings, LLC (alternate name Two River LLC) from 2004 to 2009. He has been a Director of Wave Life Sciences Ltd. since April 2014. Dr. Bolno was a resident in General Surgery at the University of Massachusetts and Hahnemann University Hospital. He was a general surgery resident and completed his Post Doctoral Research Fellowship in Cardiothoracic Surgery at Drexel University. His research focused on directing stem cells for cardiac repair as well as other modalities for treating heart failure including cardiac assist devices. His research has been presented at numerous national and international meetings. He received a B.A. from Emory University and an M.D. from Hahnemann University School of Medicine. Dr. Bolno also received an M.B.A from Drexel University with a concentration in Health Care and Biotechnology.
Paul's compensation has increased whilst company is loss making.
Paul's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
Wave Life Sciences
management team in years:
The tenure for the Wave Life Sciences management team is about average.
Chief Financial Officer
Senior VP of Corporate Development & Head of Emerging Areas
Senior Vice President of Drug Discovery
Chief Medical Officer
Senior Vice President of Operations & Business Analytics
Senior Vice President of Technical Operations
Chief Human Resources Officer
Board of Directors Tenure
Average tenure and age of the
Wave Life Sciences
board of directors in years:
The tenure for the Wave Life Sciences board of directors is about average.
Wave Life Sciences (NASDAQ:WVE) Shareholders Booked A 86% Gain In The Last Three Years
Wave Life Sciences isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last 3 years Wave Life Sciences saw its revenue grow at 104% per year. … While the compound gain of 23% per year over three years is pretty good, you might argue it doesn't fully reflect the strong revenue growth.
Does Wave Life Sciences Ltd. (NASDAQ:WVE) Have A High Beta?
Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Wave Life Sciences Ltd. (NASDAQ:WVE): What Are The Future Prospects?
The most recent earnings update Wave Life Sciences Ltd.'s (NASDAQ:WVE) released in December 2018 … company earnings became less negative compared to the previous year's level … as a result of recent tailwinds
Wave Life Sciences Ltd. (NASDAQ:WVE): Time For A Financial Health Check
(NASDAQ:WVE), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Should You Worry About Wave Life Sciences Ltd.'s (NASDAQ:WVE) CEO Salary Level?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Paul Bolno's Compensation Compare With Similar Sized Companies. … is worth US$1.2b, and total annual CEO compensation is US$3.2m.
Read This Before Buying Wave Life Sciences Ltd (NASDAQ:WVE) Shares
So shareholders might well want to know whether insiders have been buying or selling shares in Wave Life Sciences Ltd (NASDAQ:WVE). … The Last 12 Months Of Insider Transactions At Wave Life Sciences. … That means that even when the share price was below the current price of US$46.83, an insider wanted to cash in some shares.
Should You Be Concerned About Wave Life Sciences Ltd's (NASDAQ:WVE) Historical Volatility?
If you're interested in Wave Life Sciences Ltd (NASDAQ:WVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).
Wave Life Sciences Ltd (NASDAQ:WVE): Should The Recent Earnings Drop Worry You?
Today I will examine Wave Life Sciences Ltd's (NASDAQ:WVE) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to how the rest of WVE's industry performed. … See our latest analysis for Wave Life Sciences? … WVE is loss-making, with the most recent trailing twelve-month earnings of -US$116.18m (from 31 March 2018), which compared to last year has become
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.